What is Leerink Partnrs’ Forecast for REGN FY2024 Earnings?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Regeneron Pharmaceuticals in a report released on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $38.10 per share for the year, up from their previous estimate of $37.10. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $7.92 EPS, Q3 2025 earnings at $9.57 EPS and Q4 2025 earnings at $9.27 EPS.

Other equities research analysts also recently issued reports about the company. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $687.27 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $75.52 billion, a PE ratio of 17.01, a P/E/G ratio of 1.59 and a beta of 0.10. The business has a fifty day simple moving average of $724.48 and a 200-day simple moving average of $930.31. Regeneron Pharmaceuticals has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of REGN. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.